ストックスクリーナーアプリを入手
9.7007
2.23%
-0.1893
前日終値:
$9.89
開ける：
$9.56
24時間の取引高:
2.88M
Relative Volume:
0.62
時価総額：
$1.58B
収益：
$1.08B
当期純損益:
$422.82M
株価収益率:
4.2547
EPS:
2.28
ネットキャッシュフロー:
$-637.33M
1週間 パフォーマンス:
-13.59%
1か月 パフォーマンス:
+22.86%
6か月 パフォーマンス:
+22.40%
1年 パフォーマンス:
+22.55%
1日の値動き範囲:
$9.5245
$10.03
1週間の範囲:
$9.1394
$11.15
52週間の値動き範囲:
$5.01
$11.97
Novavax Inc Stock (NVAX) Company Profile
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.70 | 1.61B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.52 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.59 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.47 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.17 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 開始されました | Citigroup | Sell |
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Assessing Novavax (NVAX) Valuation After Strong Earnings Beat And Return To Profitability - simplywall.st
Novavax, Inc. $NVAX Stock Position Lowered by Vanguard Group Inc. - MarketBeat
Novavax (NVAX) EVP Elaine O'Hara receives major RSU and option grants - Stock Titan
[Form 4] NOVAVAX INC Insider Trading Activity - Stock Titan
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
NVAX: Pivoting to a partnership-driven model, the company targets profitability by 2028 with robust pipeline and deals - TradingView
Is Novavax, Inc. (NVAX) a Good Buy at the Moment? - Bitget
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - Yahoo Finance
NVAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Trading Systems Reacting to (NVAX) Volatility - Stock Traders Daily
Sanofi Takes Charge of Novavax COVID Vaccine, Mixed Financial Projections Ahead - StocksToTrade
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-02-28 - Seeking Alpha
Novavax Stock Faces Uncertain Future Amid Low Revenue Guidance - StocksToTrade
Assessing Novavax (NVAX) Valuation After Surprise Q4 Profitability And New Pfizer Licensing Deal - Yahoo Finance
How The Novavax (NVAX) Story Is Shifting Toward Licensing Income And COVID Recalibration - Yahoo Finance
Novavax (NASDAQ:NVAX) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax (NASDAQ:NVAX) Trading Down 9.8%Here's What Happened - MarketBeat
Why Novavax (NVAX) Shares Are Falling Today - Finviz
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX) - Seeking Alpha
Novavax (NASDAQ:NVAX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Novavax stock price target on guidance beat - Investing.com
NVAX: HC Wainwright & Co. Raises Price Target Amidst Buy Rating - GuruFocus
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Zacks Investment Research
NVAX Q4 Deep Dive: Partnership-Led Strategy and Pipeline Transition Shape Outlook - Finviz
Novavax to Participate in Upcoming Investor Conferences - Sahm
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax Q4 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Quarterly Earnings Results, Beats Expectations By $0.77 EPS - MarketBeat
What's Going On With Novavax Stock On Friday? - Bitget
NVV1.F Novavax, Inc. (XETRA) up 15.65% pre-market 27 Feb 2026: earnings catalyst - Meyka
Novavax Inc (NVAX) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Novavax (NVAX) Turns Profitable With US$440 Million TTM Net Income Challenging Bearish Views - simplywall.st
Novavax raises revenue forecast on boost from vaccine deals, shares soar - marketscreener.com
Novavax jumps as Q4 profit, higher revenue, and partnership milestones highlight a pivot to licensing - Quiver Quantitative
Novavax (NVAX) Reports Strong Q4 2025 Revenue Growth and Strategic Partnerships - GuruFocus
Novavax outlook 2026 adjusted total revenue $230 mln$270 mln - marketscreener.com
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals - marketscreener.com
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb - Benzinga
Why Is Novavax (NVAX) Stock Soaring Today - Yahoo Finance
Novavax’s stock soars on expected revenue jump from big pharma deals - The Business Journals
Novavax Q4 2025 slides: earnings beat fuels partnership transformation - Investing.com
Novavax Q4 2025 slides: earnings beat fuels partnership transformation By Investing.com - Investing.com South Africa
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Sees Unusually High Options Volume (NASDAQ:NVAX) - MarketBeat
Earnings call transcript: Novavax Q4 2025 earnings beat expectations, stock rises - Investing.com India
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
Novavax Inc (NVAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
59,600 |
0 |
111,706 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
4,000 |
0 |
65,159 |
| Jacobs John C | President and CEO |
Jan 23 '26 |
Option Exercise |
0.00 |
83,197 |
0 |
219,929 |
| Casey Mark J | EVP, Chief Legal Officer |
Dec 11 '25 |
Option Exercise |
0.00 |
41,899 |
0 |
73,972 |
4.32%
大文字化:
|
ボリューム (24 時間):